Cognition & mood

Focus, memory, anxiety and mood. Ranked by evidence grade, then user score. Each grade is for the use named on the card, which may not be this goal.

10 of 10 peptides shown

  1. B

    1.Cerebrolysin

    Moderate human evidence · for cognitive and functional recovery in dementia, stroke rehabilitation and traumatic brain injury (the nationally authorised uses); healthy-person nootropic use is untested

    FDA Not approved WADA Not named
    User score
    Outcomes: Positive 4 of 13 (31%), Mixed 3 of 13 (23%), Negative 1 of 13 (8%), No effect 1 of 13 (8%), Unclear 4 of 13 (31%)
    Men 45–60: 0 · everyone: 13 reports · approximate

    Why it’s listed: graded use mentions it; 5 of 13 user reports mention cognition focus.

  2. C

    2.Kisspeptin-10

    Preliminary human data · for testosterone / libido support

    FDA Not approved WADA Prohibited (S2.2.1)
    User score
    Outcomes: Positive 10 of 14 (71%), Mixed 2 of 14 (14%), No effect 1 of 14 (7%), Unclear 1 of 14 (7%)
    Men 45–60: 0 · everyone: 14 reports · approximate

    Why it’s listed: 4 of 14 user reports mention mood anxiety.

  3. C

    3.Selank

    Preliminary human data · for anxiety relief

    FDA Not approved WADA Not named
    User score
    Outcomes: Positive 6 of 11 (55%), Mixed 1 of 11 (9%), Negative 1 of 11 (9%), No effect 2 of 11 (18%)
    Men 45–60: 0 · everyone: 11 reports · approximate

    Why it’s listed: graded use mentions it; substance class mentions it; page tags mentions it; summary mentions it; 6 of 11 user reports mention mood anxiety.

  4. C

    4.Semax

    Preliminary human data · for nootropic / cognitive enhancement

    FDA Not approved WADA Not named
    User score
    Outcomes: Positive 29 of 61 (48%), Mixed 18 of 61 (30%), Negative 4 of 61 (7%), No effect 5 of 61 (8%), Unclear 5 of 61 (8%)
    Men 45–60: 0 · everyone: 61 reports · approximate

    Why it’s listed: graded use mentions it; substance class mentions it; 31 of 61 user reports mention cognition focus.

  5. C

    5.Nicotinamide adenine dinucleotide, oxidized form

    Preliminary human data · for NAD+ infusions/injections for energy, cognition and anti-ageing

    FDA Not approved WADA Not named
    User score
    Outcomes: Positive 11 of 30 (37%), Mixed 6 of 30 (20%), Negative 8 of 30 (27%), No effect 1 of 30 (3%), Unclear 4 of 30 (13%)
    Men 45–60: 1 · everyone: 30 reports · approximate

    Why it’s listed: graded use mentions it.

  6. C

    6.Pinealon

    Preliminary human data · for cognition, sleep and neuroprotection

    FDA Not approved WADA Likely prohibited (S0)
    User score
    Outcomes: Positive 4 of 10 (40%), Mixed 1 of 10 (10%), Negative 4 of 10 (40%), No effect 1 of 10 (10%), Unclear 1 of 10 (10%)
    Men 45–60: 0 · everyone: 10 reports · approximate

    Why it’s listed: graded use mentions it; 3 of 10 user reports mention cognition focus.

  7. D

    7.PE-22-28

    Preclinical only · for mood and cognition

    FDA Not approved WADA Likely prohibited (S0)
    User score
    Outcomes: Positive 4 of 11 (36%), Mixed 1 of 11 (9%), Negative 4 of 11 (36%), No effect 2 of 11 (18%)
    Men 45–60: 0 · everyone: 11 reports · approximate

    Why it’s listed: graded use mentions it; 3 of 11 user reports mention mood anxiety.

  8. D

    8.Adamax

    Preclinical only · for nootropic

    FDA Not approved WADA Likely prohibited (S0)
    User scoretoo few reports (4)
    Men 45–60: 0 · everyone: 4 reports · approximate

    Why it’s listed: graded use mentions it; 2 of 4 user reports mention cognition focus; 3 of 4 user reports mention mood anxiety.

  9. D

    9.Dihexa

    Preclinical only · for nootropic / cognitive repair

    FDA Not approved WADA Likely prohibited (S0)
    User scoretoo few reports (9)
    Men 45–60: 0 · everyone: 9 reports · approximate

    Why it’s listed: graded use mentions it; 3 of 9 user reports mention cognition focus.

  10. D

    10.Humanin

    Preclinical only · for longevity, metabolic and neuroprotective use

    FDA Not approved WADA Likely prohibited (S0)
    User scoretoo few reports (7)
    Men 45–60: 0 · everyone: 7 reports · approximate

    Why it’s listed: 2 of 7 user reports mention mood anxiety.

User reports are anecdata, not evidence: self-selected, unverified, often combined with other compounds.